Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Wahed FTSE USA Shariah ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Wahed FTSE USA Shariah ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Wahed FTSE USA Shariah ETF trades at $72.96. Which is the better fit depends on your goals.

ACADHLAL
Market Cap
$5.07B
Sector
HealthSector/Thematic
52-Week High
$29.41$73.60
52-Week Low
$20.06$55.52
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

Wahed FTSE USA Shariah ETF

HLAL trades at $72.93, showing minimal daily movement with a slight 0.06% decline. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while the stock lacks comprehensive fundamental data for traditional valuation metrics. The upcoming dividend of $0.02 per share scheduled for June 2026 provides a modest income component.

The stock's outlook remains uncertain due to limited financial disclosures. Investment opportunity hinges on future earnings visibility and market positioning, while primary risks include information gaps and market volatility. Further fundamental analysis requires updated SEC filings and earnings reports to assess true valuation potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Wahed FTSE USA Shariah ETF

HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.

Read more on HLAL